1. Home
  2. DAWN vs SCHL Comparison

DAWN vs SCHL Comparison

Compare DAWN & SCHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • SCHL
  • Stock Information
  • Founded
  • DAWN 2018
  • SCHL 1920
  • Country
  • DAWN United States
  • SCHL United States
  • Employees
  • DAWN N/A
  • SCHL N/A
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • SCHL Books
  • Sector
  • DAWN Health Care
  • SCHL Consumer Discretionary
  • Exchange
  • DAWN Nasdaq
  • SCHL Nasdaq
  • Market Cap
  • DAWN 624.8M
  • SCHL 644.1M
  • IPO Year
  • DAWN 2021
  • SCHL 1987
  • Fundamental
  • Price
  • DAWN $7.15
  • SCHL $27.53
  • Analyst Decision
  • DAWN Strong Buy
  • SCHL Strong Buy
  • Analyst Count
  • DAWN 7
  • SCHL 1
  • Target Price
  • DAWN $27.86
  • SCHL $37.00
  • AVG Volume (30 Days)
  • DAWN 1.1M
  • SCHL 234.9K
  • Earning Date
  • DAWN 10-29-2025
  • SCHL 09-18-2025
  • Dividend Yield
  • DAWN N/A
  • SCHL 2.91%
  • EPS Growth
  • DAWN N/A
  • SCHL N/A
  • EPS
  • DAWN N/A
  • SCHL N/A
  • Revenue
  • DAWN $187,638,000.00
  • SCHL $1,625,500,000.00
  • Revenue This Year
  • DAWN $12.56
  • SCHL $4.15
  • Revenue Next Year
  • DAWN $48.02
  • SCHL $3.96
  • P/E Ratio
  • DAWN N/A
  • SCHL N/A
  • Revenue Growth
  • DAWN 2190.50
  • SCHL 2.25
  • 52 Week Low
  • DAWN $5.64
  • SCHL $15.77
  • 52 Week High
  • DAWN $16.76
  • SCHL $34.18
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 51.15
  • SCHL 64.18
  • Support Level
  • DAWN $7.03
  • SCHL $25.73
  • Resistance Level
  • DAWN $7.58
  • SCHL $26.92
  • Average True Range (ATR)
  • DAWN 0.27
  • SCHL 0.90
  • MACD
  • DAWN -0.04
  • SCHL 0.11
  • Stochastic Oscillator
  • DAWN 29.55
  • SCHL 83.61

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

About SCHL Scholastic Corporation

Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.

Share on Social Networks: